Balapiravir

Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine) . Balapiravir has anti-HCV activity[1][2][3]. Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Product Specifications

CAS Number

[690270-29-2]

Product Name Alternative

Ro 4588161; R1626

UNSPSC

12352005

Target

DNA/RNA Synthesis; HCV

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Balapiravir.html

Purity

97.22

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C1N=C(N)C=CN1[C@@H]2O[C@](N=[N+]=[N-])(COC(C(C)C)=O)[C@@H](OC(C(C)C)=O)[C@H]2OC(C(C)C)=O

Molecular Formula

C21H30N6O8

Molecular Weight

494.50

References & Citations

[1]Nguyen NM, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013 May 1;207 (9) :1442-1450.|[2]Nelson DR, et al. Balapiravir plus peginterferon alfa-2a (40KD) /ribavirin in a randomized trial of hepatitis C genotype 1 patients.Ann Hepatol. 2012 Jan-Feb;11 (1) :15-31.|[3]Yen-Liang Chen, et al. Activation of Peripheral Blood Mononuclear Cells by Dengue Virus Infection Depotentiates Balapiravir. J Virol. 2014 Feb;88 (3) :1740-7.